1430 related articles for article (PubMed ID: 17132032)
1. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
2. Patient access to pharmaceuticals: an international comparison.
Cohen J; Faden L; Predaris S; Young B
Eur J Health Econ; 2007 Sep; 8(3):253-66. PubMed ID: 17279403
[TBL] [Abstract][Full Text] [Related]
3. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
[TBL] [Abstract][Full Text] [Related]
4. The lag from FDA approval to published cost-utility evidence.
Chambers JD; Thorat T; Pyo J; Neumann PJ
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):399-402. PubMed ID: 25579324
[TBL] [Abstract][Full Text] [Related]
5. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
Robinson SW; Brantley K; Liow C; Teagarden JR
J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan.
Oye KA; Eichler HG; Hoos A; Mori Y; Mullin TM; Pearson M
Clin Pharmacol Ther; 2016 Dec; 100(6):626-632. PubMed ID: 27618128
[TBL] [Abstract][Full Text] [Related]
8. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
9. Coverage of New Drugs in Medicare Part D.
Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
[TBL] [Abstract][Full Text] [Related]
10. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
Shaw DL; Dhruva SS; Ross JS
J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
[TBL] [Abstract][Full Text] [Related]
11. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
Ghadanian M; Schafheutle E
Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
[TBL] [Abstract][Full Text] [Related]
12. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
13. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020.
Pham C; Le K; Draves M; Seoane-Vazquez E
JAMA Intern Med; 2023 Apr; 183(4):290-297. PubMed ID: 36780147
[TBL] [Abstract][Full Text] [Related]
14. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand.
Raftery JP
Med J Aust; 2008 Jan; 188(1):26-8. PubMed ID: 18205559
[TBL] [Abstract][Full Text] [Related]
15. Patient access to new cancer drugs in the United States and Australia.
Wilson A; Cohen J
Value Health; 2011; 14(6):944-52. PubMed ID: 21914517
[TBL] [Abstract][Full Text] [Related]
16. AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.
J Manag Care Spec Pharm; 2017 Jan; 23(1):105-112. PubMed ID: 28025919
[TBL] [Abstract][Full Text] [Related]
17. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?
Mauskopf J; Chirila C; Birt J; Boye KS; Bowman L
Health Policy; 2013 Apr; 110(1):49-59. PubMed ID: 23434292
[TBL] [Abstract][Full Text] [Related]
18. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
Leyens L; Brand A
Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
[TBL] [Abstract][Full Text] [Related]
19. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
[TBL] [Abstract][Full Text] [Related]
20. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]